All In Biotech

Drug Trial Radar · NCT02366546

Investigator Initiated Phase 1 Study of TBI-1301

Multi-center, Investigator Initiated Phase 1 Study of NY-ESO-1 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

9

Actual

Start

Mar 2015

Primary completion

Sep 2018

Sponsor

Lead sponsor
Mie UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Takara Bio Inc.; Shionogi; Fiverings Co., Ltd.; Statcom Co. Ltd.
First posted
Feb 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.

Conditions

  • Solid Tumors

Interventions

  • TBI-1301Drug

    TBI-1301(5\*10\^8 or 5\*10\^9) is administered.

  • CyclophosphamideDrug

    Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

  • FludarabineDrug

    Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and grade of adverse events (CTCAE)Time frame: 4 weeks
  2. Appearance of replication competent retrovirus by PCRTime frame: 4 weeks
  3. Appearance of clonality by LAM-PCRTime frame: 4 weeks
  4. Kinetics of TBI-1301 in blood by realtime-PCRTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mie University Hospital

    Tsu, Mie-ken, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.